

Identity:

Title: Professor

Family Name(s): Dana

First Name(s): Dawson

Age: 56 years

Photo:**Application for the following position in the HFA Board or Nominating Committee:**

Ordinary Board member

Place of work

If you work in multiple places, please provide the one where you spend the most time or that you consider to be your main place of practice.

Institute/organisation: University of Aberdeen and Aberdeen Royal Infirmary

Department: Cardiology and Cardiovascular Medicine

Address: Level 1 Aberdeen Royal Infirmary, Foresterhill, Aberdeen

Post code / Zip: AB25 2ZD

Country: Scotland, United Kingdom

General Curriculum Vitae (500 words max)

Please also include your H index and top 5 to 10 publications in the last 5 years

H-index: 44 (<http://scholar.google.co.uk/citations?user=wm5th-YAAAAJ&hl=en>)
<https://orcid.org/0000-0003-2815-4469>

1. [Intramyocellular Saturated Fatty Acid Abundance and Turnover as an Index of Exercise-driven Metabolic Health](#) - A M Mezincescu, A Rudd, L Cheyne, G Horgan, S Philip, D Cameron, L van Loon, P Whitfield, R Gribbin, M Delibegovic, G Lobley, F Thies, B Fielding, A Henning, **D K Dawson**, *in press*, **Nature Communications**, 2024
2. [Cardiovascular and Non-cardiovascular Prescribing and Mortality After Takotsubo - Comparison With Myocardial Infarction and General Population](#), Amelia E. Rudd, Graham Horgan, Hilal Khan, David T. Gamble, Jim McGowan, Arvind Sood, Ross McGeoch, John Irving, Jonathan Watt, Stephen J. Leslie, Mark Petrie, Chim Lang, Nicholas L. Mills, David E. Newby, **Dana K. Dawson**, **JACC Adv.** Jan 10, 2024. Epublished DOI: 10.1016/j.jacadv.2023.100797
3. [Impaired cardiac and skeletal muscle energetics following anthracycline therapy for breast cancer](#), D Gamble, J Ross, H Khan, A Unger, L Cheyne, A Rudd, F Saunders, J Srivanasan, S Kanya, G Horgan, A Hannah, S Baliga, CG Tocchetti, G Urquhart, W Linke, Y Mazannat, A Mustafa, M Fuller, B Elsberger, R Sharma, **Dana Dawson**, **Circ Cardiovasc Imaging**. 2023 Oct;16(10):e015782. doi: 10.1161/CIRCIMAGING.123.015782. Epub 2023
4. [Structural and Functional Brain Changes in Acute Takotsubo Syndrome](#). Khan H, Gamble DT, Rudd A, Mezincescu AM, Abbas H, Noman A, Stewart A, Horgan G, Krishnadas R, Williams C, Waiter GD, **Dawson DK**. **JACC Heart Fail.** 2023 Mar;11(3):307-317. doi: 10.1016/j.jchf.2022.11.001.
5. [Myocardial infarction risk is increased by periodontal pathobionts: a cross-sectional study](#). Joshi C, Mezincescu A, Gunasekara M, Rudd A, Botchorichvili H, Sabir S, Dospinescu C, Noman A, Hogg D, Cherukara G, McLernon D, Hijazi K, **Dawson D**. **Sci Rep.** 2022 Nov 3;12(1):18608. doi: 10.1038/s41598-022-19154-z.
6. [Metabolic alterations in a rat model of takotsubo syndrome](#). Godsman N, Kohlhaas M, Nickel A, Cheyne L, Mingarelli M, Schweiger L, Hepburn C, Munts C, Welch A,

Delibegovic M, Van Bilsen M, Maack C, Dawson DK. *Cardiovasc Res*. 2022 Jun 29;118(8):1932-1946. doi: 10.1093/cvr/cvab081.

7. [Takotsubo Syndrome: Pathophysiology, Emerging Concepts, and Clinical Implications](#). Singh T, Khan H, Gamble DT, Scally C, Newby DE, Dawson D. *Circulation*. 2022 Mar 29;145(13):1002-1019. doi: 10.1161/CIRCULATIONAHA.121.055854.
8. [Persistent Long-Term Structural, Functional, and Metabolic Changes After Stress-Induced \(Takotsubo\) Cardiomyopathy](#). Scally C, Rudd A, Mezincescu A, Wilson H, Srinivasan J, Horgan G, Broadhurst P, Newby DE, Henning A, Dawson DK. *Circulation*. 2018;137:1039-1048. doi: 10.1161/CIRCULATIONAHA.117.031841. Reviewed as "Takotsubo has long-lasting functional consequences" in *Nature Reviews Cardiology* volume 15, page 6 (2018)
9. [Myocardial and Systemic Inflammation in Acute Stress-Induced \(takotsubo\) Cardiomyopathy](#). Caroline Scally, Hassan Abbas, Trevor Ahearn, Janaki Srinivasan, Alice Mezincescu, Amelia Rudd, Nicholas Spath, Alim Yucel-Finn, Raif Yuecel, Keith Oldroyd, Ciprian Dospinescu, Graham Horgan, Paul Broadhurst, Anke Henning, David Newby, Scott Semple, Heather Wilson, and Dana Dawson, *in press, Circulation*. 2019 Mar 26;139(13):1581-1592. doi: 10.1161/CIRCULATIONAHA.118.037975, reviewed as "Inflammation linked to Takotsubo" in *Nature Reviews Cardiology* (2018)
10. [Common genetic variants and modifiable risk factors underpin hypertrophic cardiomyopathy -susceptibility and expressivity](#). Harper AR, Goel A, Grace C, Thomson KL, Petersen SE, Xu X, Waring A, Ormondroyd E, Kramer CM, Ho CY, Neubauer S; HCMR Investigators, Tadros R, Ware JS, Bezzina CR, Farrall M, Watkins H. Harper AR, et al. *Nat Genet*. 2021 Jan 25. doi: 10.1038/s41588-020-00764-0.

Describe previous experience within the HFA, ESC and/or your National Cardiac/ HF Society

150 words maximum

I am the current Chair of the Working Group on Myocardial Function (2022-24) and Lead of the Takotsubo Study Group of the HFA. I am also a member of the Scientific Committees of the Myocardial/Pericardial Diseases Working Group, of EACVI, and of the British Society of Cardiovascular Magnetic Resonance Imaging Research Group. I sit on the British Heart Foundation Fellowships Committee in the UK.

I have navigated the difficult post-pandemic times for the Myocardial Function Working Group, through effective coordination with the WG Nucleus members and a close collaborative effort with the HFA presidential trio.

Why are you motivated to join the HFA Board or Nominating Committee?

150 words maximum

I am a clinician scientist with a strong translational pursuit, at the interface between clinical and basic sciences research. I wish to bring this breadth of knowledge and experience to the HFA Board, for better integration of all research into clinical guidelines, drafting of agenda setting strategies of the Board, better heart failure care and dissemination of clinical trials into clinical care of heart failure patients. I have a particular interest in a specific heart failure syndrome, that of takotsubo, in which I conduct world leading mechanistic and big data clinical research. The insights learned from this work, and also those of cardio-oncology and diabetic cardiomyopathy equip me well for continuing to serve scientific and strategic roles on the HFA Board. I feel that my experience as Chair of the

Myocardial Function working group lends itself into this transition and it is with great enthusiasm that I will offer my services to support the Board and the Presidential Trio in developing the future roadmap of the HFA.

How will you combine your HFA position with your daily clinical/research workload?

80 words maximum

This is a natural extension of the work I currently do, as with diminishing roles when I become Past-Chair of the Myocardial Function Working Group (after Aug 2024), I will be able to fully devote my time to the HFA Board and the Takotsubo Study group of the HFA.